24 March 2017 in Scientific Reports
Membrane protein production is usually toxic to E. coli. However, using genetic screens strains can be isolated in which the toxicity of membrane protein production is reduced, thereby improving production yields. Best known examples are the C41(DE3) and C43(DE3) strains, which are both derived from the T7 RNA polymerase (P)-based BL21(DE3) protein production strain. In C41(DE3) and C43(DE3) mutations lowering t7rnap expression levels result in strongly reduced T7 RNAP accumulation levels. As a consequence membrane protein production stress is alleviated in the C41(DE3) and C43(DE3) strains, thereby increasing membrane protein yields. Here, we isolated Mutant56(DE3) from BL21(DE3) using a genetic screen designed to isolate BL21(DE3)-derived strains with mutations alleviating membrane protein production stress other than the ones in C41(DE3) and C43(DE3). The defining mutation of Mutant56(DE3) changes one amino acid in its T7 RNAP, which weakens the binding of the T7 RNAP to the T7 promoter governing target gene expression rather than lowering T7 RNAP levels. For most membrane proteins tested yields in Mutant56(DE3) were considerably higher than in C41(DE3) and C43(DE3). Thus, the isolation of Mutant56(DE3) shows that the evolution of BL21(DE3) can be promoted towards further enhanced membrane protein production.
16 September 2013 in Bioconjugate Chemistry
1 September 2015 in Analytical Biochemistry
1 May 2015 in Journal of Controlled Release
15 May 2019 in Tissue Engineering Part A
LBLaura L. Cárdenas Bonilla
Laura L. Cárdenas Bonilla
+7
Naturally occurring antimicrobial peptides (AMPs) are effector molecules secreted by several cell types but especially by cells of the innate immune system such as macrophages. AMPs largely avoid resistance acquired by bacteria to man-made antibiotics. Different short chain fatty acids (SCFAs) have proven to be efficient inducers of AMP secretion. The SCFA butyrate is an endogenous histone deacetylase inhibitor that has been shown to induce the expression of the AMP cramp (cathelicidin LL-37) in cells of the immune system and mucosal epithelium, which provides protection against pathogens. Clinical applications of butyrate, however, are limited due to its cytotoxic effects. Hydroxylated derivatives of butyrate (2-hydroxybutyrate [2HB], 3-hydroxybutyrate [3HB], and 4-hydroxybutyrate [4HB]) are also endogenous molecules, but their capability of inducing AMP expression has been unexplored. 4HB has been used for the production of polymeric surgical meshes intended for soft tissue repair. This study evaluated the ability of hydroxylated derivatives of butyrate to induce the upregulation of AMPs in murine bone marrow-derived macrophages in vitro . Noncytotoxic effects and increased cramp and β-defensin-4 were found to be induced by 4HB. An in vivo increased resistance to deliberate bacterial contamination was shown by a surgical mesh composed of a polymer of 4HB compared with polypropylene surgical mesh. Impact Statement: This study evaluated the biological activity of hydroxylated derivatives of butyrate as inductors of antimicrobial peptides (AMPs) in murine bone marrow-derived macrophages in vitro . A differential modulation of AMP expression by the hydroxylated derivatives of butyrate is shown. The ability of sodium 4-hydroxybutyrate to upregulate AMP expression through a histone deacetylase inhibitory-independent mechanism, and to promote increased resistance to bacterial contamination in vivo are also shown. The findings provide an alternative for prevention of bacterial contamination of implanted biomaterials. Functionalization of biomaterials with hydroxylated derivatives of butyrate can enhance the endogenous antimicrobial activity of the immune system through increased production of AMPs by host cells, thus providing protection against bacterial contamination.
1 January 2013 in Frontiers in Bioscience-Elite
The field of gene therapy is starting to move towards clinical applications but is currently limited by the lack of efficient delivery systems. Cell-penetrating peptides provide a means of cellular delivery for gene therapy applications as well as delivery of traditional drugs. Using cell-penetrating peptides a range of different cargos have been successfully delivered into a number of cell types, in vitro as well as in vivo. In this review we discuss uptake mechanisms of different cell-penetrating peptides, with or without cargo. The transition from in vitro to in vivo applications and strategies to increase the bioavailability of cell-penetrating peptides are also discussed.